Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 76200L309 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Balyasny Asset Management L.P.
13G/A
Amendment 1
|
4.8% |
8/14/2026
Event 6/30/2026
|
|
| Balyasny Asset Management L.P. | 4.8% | ||
| Bam GP LLC | 4.8% | ||
| Balyasny Asset Management Holdings LP | 4.8% | ||
| Dames GP LLC | 4.8% | ||
| Dmitry Balyasny | 4.8% | ||
|
Dellora Investments LP
13G
|
5.9% |
8/12/2026
Event 8/5/2026
|
|
| Dellora Investments Master Fund LP | 5.1% | ||
| Dellora Investments LP | 5.9% | ||
| Kevin Pyun | 5.9% | ||
| Bank of America Corp /DE/ 13G/A Amendment 1 | 1.2% |
8/12/2026
Event 6/30/2026
|
|
|
Balyasny Asset Management L.P.
13G
|
5.3%
Checked 5% or less
|
5/15/2026
Event 3/31/2026
|
|
| Balyasny Asset Management L.P. | 5.3% | ||
| Bam GP LLC | 5.3% | ||
| Balyasny Asset Management Holdings LP | 5.3% | ||
| Dames GP LLC | 5.3% | ||
| Dmitry Balyasny | 5.3% | ||
|
Opaleye Management Inc.
13G/A
Amendment 2
|
6.6% |
5/11/2026
Event 3/31/2026
|
|
| Opaleye Management Inc. | 6.6% | ||
| Opaleye, L.P. | 6.4% | ||
| James Silverman | 6.6% | ||
| Vanguard Group Inc 13G/A Amendment 1 | 0% |
3/26/2026
Event 3/13/2026
|
|
|
Invus Global Management, LLC
13G/A
Amendment 1
|
0% |
2/13/2026
Event 12/31/2025
|
|
| Invus Public Equities, L.P. | 0% | ||
| Invus Public Equities Advisors, LLC | 0% | ||
| Invus Global Management, LLC | 0% | ||
| Siren, L.L.C. | 0% | ||
| Avicenna Life Sci Master Fund LP | 0% | ||
| Avicenna Life Sci Master GP LLC | 0% | ||
| Ulys, L.L.C. | 0% | ||
| Raymond Debbane | 0% | ||
| Bank of America Corp /DE/ 13G | 6.5% |
2/11/2026
Event 12/31/2025
|
|
| Vanguard Group Inc 13G | 5.2% |
1/30/2026
Event 12/31/2025
|
|
|
FMR LLC
13G/A
Amendment 2
|
2.5% |
1/8/2026
Event 12/31/2025
|
|
| FMR LLC | 2.5% | ||
| Abigail P. Johnson | 2.5% | ||
|
Opaleye Management Inc.
13G
|
5.3% |
12/19/2025
Event 12/12/2025
|
|
| Opaleye Management Inc. | 5.3% | ||
| Opaleye, L.P. | 5.2% | ||
| James Silverman | 5.3% | ||
|
RA Capital Management, L.P.
13G
|
9.9% |
12/18/2025
Event 12/11/2025
|
|
| RA Capital Management, L.P. | 9.9% | ||
| Peter Kolchinsky | 9.9% | ||
| Rajeev Shah | 9.9% | ||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||
| BlackRock, Inc. 13G | 5.4% |
10/17/2025
Event 9/30/2025
|
|
|
Invus Global Management, LLC
13G
|
5.4% |
9/22/2025
Event 9/18/2025
|
|
| Invus Public Equities, L.P. | 4.6% | ||
| Invus Public Equities Advisors, LLC | 4.6% | ||
| Invus Global Management, LLC | 4.6% | ||
| Siren, L.L.C. | 4.6% | ||
| Avicenna Life Sci Master Fund LP | 0.8% | ||
| Avicenna Life Sci Master GP LLC | 0.8% | ||
| Ulys, L.L.C. | 0.8% | ||
| Raymond Debbane | 5.4% | ||
|
FMR LLC
13G/A
Amendment 1
|
15.0% |
8/6/2025
Event 6/30/2025
|
|
| FMR LLC | 15.0% | ||
| Abigail P. Johnson | 15.0% | ||
|
FMR LLC
13G
|
10.5% |
3/7/2025
Event 2/28/2025
|
|
| FMR LLC | 10.5% | ||
| Abigail P. Johnson | 10.5% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 2
|
4.9% |
2/14/2025
Event 12/31/2024
|
|
| Nantahala Capital Management, LLC | 4.9% | ||
| Wilmot B. Harkey | 4.9% | ||
| Daniel Mack | 4.9% | ||
|
Nantahala Capital Management, LLC
13G/A
Amendment 1
|
8.6% |
11/14/2024
Event 9/30/2024
|
|
| Nantahala Capital Management, LLC | 8.6% | ||
| Wilmot B. Harkey | 8.6% | ||
| Daniel Mack | 8.6% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 2.95 k | $12.2 k |
| 2026 Q2 | 152 | 86.6 M | $451 M |
| 2026 Q1 | 133 | 86.3 M | $263 M |
| 2025 Q4 | 140 | 90.6 M | $214 M |
| 2025 Q3 | 125 | 87.0 M | $817 M |
| 2025 Q2 | 100 | 77.9 M | $348 M |
| 2025 Q1 | 84 | 45.0 M | $131 M |
| 2024 Q4 | 77 | 43.2 M | $212 M |
| 2024 Q3 | 64 | 38.9 M | $189 M |
| 2024 Q2 | 56 | 42.9 M | $185 M |
| 2024 Q1 | 36 | 27.0 M | $69.0 M |
| 2023 Q4 | 36 | 30.5 M | $30.3 M |
| 2023 Q3 | 31 | 23.9 M | $31.5 M |
| 2023 Q2 | 30 | 24.2 M | $48.0 M |
| 2023 Q1 | 33 | 24.2 M | $46.5 M |
| 2022 Q4 | 36 | 24.5 M | $50.7 M |
| 2022 Q3 | 35 | 25.7 M | $70.3 M |
| 2022 Q2 | 36 | 24.5 M | $79.2 M |
| 2022 Q1 | 22 | 7.09 M | $24.0 M |
| 2021 Q4 | 24 | 7.53 M | $36.0 M |
| 2021 Q3 | 15 | 2.37 M | $17.6 M |
| 2021 Q2 | 13 | 2.21 M | $31.6 M |
| 2021 Q1 | 12 | 2.48 M | $17.5 M |
| 2020 Q4 | 9 | 2.51 M | $30.2 M |